Table 1.
Numbers of mice examined from each genotype, from each line, for each of the physiological and histological analyses performed in the present study
| α1 |
α2 |
α5 |
α6 |
β2 |
β3 |
δ |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 weeks | 6 weeks | 1.5 weeks | 3 weeks | 6 weeks | 24 weeks | 6 weeks | 1.5 weeks | 3 weeks | 6 weeks | 24 weeks | 6 weeks | 24 weeks | 6 weeks | ||
| Thresholds (ABR) | +/+ 4 | +/+ 10 | +/+ 15 | +/+ 12 | +/+ 17 | +/+ 13 | +/+ 8 | +/+ 13 | |||||||
| −/− 7 | −/− 8 | −/− 8 | −/− 10 | −/− 7 | −/−22 | −/− 22 | +/− 11 | −/− 11 | |||||||
| −/− 17 | |||||||||||||||
| Thresholds (DPOAE) | +/+ 9 | +/+ 17 | +/+ 29 | +/+ 23 | +/+ 33 | +/+ 23 | +/+ 16 | +/+ 26 | |||||||
| −/− 13 | −/− 16 | −/− 35 | −/− 20 | −/− 14 | −/− 48 | −/− 29 | +/− 22 | −/− 22 | |||||||
| −/− 17 | |||||||||||||||
| Efferent function | +/+ 12 | +/+ 4 | +/+ 11 | +/+ 6 | +/+ 8 | ||||||||||
| −/− 10 | −/− 6 | −/− 9 | −/− 17 | −/− 5 | |||||||||||
| Cochlear vulnerability | +/+ 5 | +/+ 6 | |||||||||||||
| −/− 6 | −/− 9 | ||||||||||||||
| Cochlear pathology | +/+ 2 | +/+ 2 | +/+ 2 | ** | +/+ 4 | +/+ 2 | +/+ 2 | +/+ 2 | |||||||
| −/− 2 | −/− 2 | −/− 2 | −/− 3 | −/− 2 | −/− 5 | −/− 2 | −/− 3 | −/− 2 | −/− 2 | ||||||
| Cochlear innervation | +/+ 2 | +/+ 1 | +/+ 1 | +/+ 1 | ** | +/+ 1 | +/+ 2 | +/+ 1 | |||||||
| −/− 2 | −/− 2 | −/− 1 | −/− 3 | −/− 2 | −/− 2 | −/− 3 | −/− 2 | ||||||||
**, Data from genetically identical β 2 or α 5 +/+ ears were used. All animals examined for histopathology were also tested by ABR and DPOAE. Results of ABR and DPOAE tests are shown in Figures 1 and 2 and supplemental Figure S1 (available at www.jneurosci.org as supplemental material). Results of the assay for efferent function are shown in Figure 3 and supplemental Figure S2 (available at www.jneurosci.org as supplemental material), for cochlear vulnerability in Figure 4, for cochlear histopathology in Figures 5 and 6, and for cochlear innervation in Figures 7–9.